← Oncology Approval Tracker

FDA DECISION ·

Braftovi + cetuximab + mFOLFOX6

encorafenib with cetuximab and mFOLFOX6 · Array BioPharma (Pfizer)

Accelerated approvalNew or expanded indicationColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Feb 24, 2026

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Patients with metastatic colorectal cancer and an FDA test-confirmed BRAF V600E mutation, treated with encorafenib, cetuximab and mFOLFOX6.

LAMPGEN ANALYSIS

Why it matters

The December action brought a BRAF-directed combination into frontline use; distinguish it from the chemotherapy-free doublet used after prior therapy. The FDA granted traditional approval in February 2026.

What research teams should watch

Get BRAF results before selecting a first regimen and track component-specific dose holds and treatment exposure.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Molecularly selected metastatic disease

PRIMARY RECORDS

Sources